3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Colorectal Neoplasms
5
Medulloblastoma
3
Colonic Neoplasms
3
Turcot syndrome
2
Triple Negative Breast Neoplasms
2
Rhabdoid Tumor
2
Recurrence
2
Pinealoma
2
Neuroblastoma
2
Ependymoma
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Solid Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pyloric Stenosis, Hypertrophic
1
Pancreatic Cancer Metastatic
1
Ovarian Neoplasms
1
Osteosarcoma
1
Oropharyngeal Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Locally Advanced Rectal Cancer
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Interventions
pembrolizumab
6
Injections
6
toripalimab
3
tislelizumab
3
senaparib
3
Bevacizumab
3
sintilimab
2
Technetium
2
Specimen Handling
2
Nivolumab
2
Ipilimumab
2
Fluorodeoxyglucose F18
2
Carboplatin
2
Blood Specimen Collection
2
zimberelimab
1
tumor-cells apoptosis factor, human
1
tazemetostat
1
spartalizumab
1
sacituzumab govitecan
1
rucaparib
1
osimertinib
1
olaparib
1
etoposide phosphate
1
enzalutamide
1
envafolimab
1
encorafenib
1
cemiplimab
1
cedazuridine
1
binimetinib
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Solid Tumor
×
Celecoxib
×
1 year
×
Clear all
NCT04469530
2026-02-27
AflacST1903
Emory University
Phase 2
Recruiting
55 enrolled